Regeneron — Deal History & Benchmarks
Market Analysis
Regeneron has been involved in 4 transactions totaling $16.5B across Rare Disease, Cardiovascular, Immunology & Autoimmune. As both a licensor and licensee, they have demonstrated a collaborative partnership model.
Key transactions include Sanofi ($13B, 2024), Alnylam ($1.4B, 2024), Alnylam Pharmaceuticals ($1.4B, 2024).
Their deal activity is concentrated in Cardiovascular (50%) with RNAi and PCSK9 Targeting assets representing their most common deal types.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How many deals has Regeneron done?
What is Regeneron's typical deal structure?
What therapeutic areas does Regeneron focus on?
How has Regeneron's deal activity trended over time?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.